Add to Favourites
To login click here
Telo Genomics Corp. presented the results of their machine learning and AI modules at the American Society of Clinical Oncology annual meeting. Their proprietary tool, CellSelect-Pro, was developed to identify and process myeloma plasma cells in patient samples, resulting in faster processing times and potential cost savings. The tool has been successfully implemented into Telo’s testing workflows and is being used in their flagship product for smoldering multiple myeloma patients.
